Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating ...

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics (AKTX) announces leadership ...

– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 ...

Tina Rivard, Director of Public Works in Sudbury, outlined the Town Walkway Prioritization Plan during a Jan. 6 Select Board ...

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value ...

Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA. “As part of the merger process, the boards of each company ...